Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): Intravirion molecular therapies

Journal of Human Virology

Volumn 3, Issue 1, 2000, Pages 6-15

  BouHamdan, Mohamad ^a   Kulkosky, Joseph ^a   Duan, Ling Xun ^a   Pomerantz, Roger J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Gene therapy; HIV 1; Intravirion; Retrovirus; Single chain variable fragment (SFv); Vpr

Indexed keywords

ANTIVIRUS AGENT; HYBRID PROTEIN; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VPR ANTIBODY SINGLE CHAIN VARIABLE FRAGMENT;

ANTIGEN EXPRESSION; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION;

ANTI-HIV AGENTS; BLOTTING, WESTERN; CELL LINE; CHLORAMPHENICOL O-ACETYLTRANSFERASE; CLONING, MOLECULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE PRODUCTS, REV; GENE PRODUCTS, VPR; GENETIC VECTORS; HELA CELLS; HIV ANTIGENS; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; INTEGRASE INHIBITORS; RECOMBINANT FUSION PROTEINS; VIRUS REPLICATION;

FELIS CATUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIMATES; UNIDENTIFIED RETROVIRUS;

EID: 0033925327     PISSN: 10909508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Morsy MA, Mitani K, Clemens P, Caskey CT. Progress toward gene therapy. JAMA 1993;270:2338-2344.
2. Miller AD, Miller DG, Garcia JV, Lynch CM. Use of retroviral vectors for gene transfer and expression. Methods Enzymol 1993;217:581-599.
3. Mulligan RC. The basic science of gene therapy. Science 1993;260:926-932.
4. Cullen BR. Mechanism of action of regulatory proteins encoded by complex retroviruses. Microbiol Rev 1992; 56:375-394.
5. Debouck C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses 1992;8:153-164.
6. Miller RH, Turk SR, Black RJ, Bridges S, Sarver N. Conference summary: novel HIV therapies - from discovery to clinical proof of concept. AIDS Res Hum Retroviruses 1996;12:859-865.
7. Ridky T, Leis J. Development of drug resistance to HIV-1 protease inhibitors. J Biol Chem 1995;270:29621-29623.
8. Richman DD. Clinical significance of drug resistance in human immunodeficiency virus. Clin Infect Dis 1995;21(Suppl 2):S166-S169.
9. Dropulic B, Jeang KT. Gene therapy for human immunodeficiency virus infection: genetic antiviral strategies and targets for intervention. Hum Gene Ther 1994;5:927-939.
10. Pomerantz RJ, Trono D. Genetic therapies for HIV infections: promise for the future. AIDS 1995;9:985-993.
11. BouHamdan M, Duan LX, Pomerantz RJ, Strayer DS. Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection. Gene Ther 1999;6:660-666.
12. Ho W-Z, Lai J-P, BouHamdan M, Duan L-X, Pomerantz RJ, Starr SE. Inhibition of HIV type 1 replication in chronically-infected monocytes and lymphocytes by retrovirus-mediated gene transfer of anti-rev single-chain variable fragments. AIDS Res Hum Retroviruses 1998;14:1573-1580.
13. Chen SY, Khouri Y, Bagley J, Marasco WA. Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody. Proc Natl Acad Sci USA 1994;91:5932-5936.
14. Levy-Mintz P, Duan L, Zhang H, et al. Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase [published erratum 1998;72:3505]. J Virol 1996;70:8821-8832.
15. Lisziewicz J, Sun D, Lisziewicz A, Gallo RC. Antitat gene therapy: a candidate for late-stage AIDS patients. Gene Ther 1995;2:218-222.
16. Liu H, Wu X, Xiao H, Conway JA, Kappes JC. Incorporation of functional human immunodeficiency virus type 1 integrase into virions independent of the Gag-Pol precursor protein. J Virol 1997;71:7704-7710.
17. + T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or tat. Hum Gene Ther 1998;9:487-496.
18. Shaheen F, Duan L-X, Zhu M, Bagasra O, Pomerantz RJ. Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle. J Virol 1996;70:3392-3400.
19. Sun LQ, Pyati J, Smythe J, et al. Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs. Proc Natl Acad Sci USA 1995;92:7272-7276.
20. Yu M, Ojwang J, Yamada O, Hampel A, Rapapport J, Looney D. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1 [published erratum 1993;90:8303]. Proc Natl Acad Sci USA 1993;90:6340-6344.
21. Cohen EA, Dehni G, Sodroski JG, Haseltine WA. Human immunodeficiency virus Vpr product is a virion-associated regulatory protein. J Virol 1990;64:3097-3099.
22. Lu YL, Spearman P, Ratner L. Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions. J Virol 1993;67:6542-6550.
23. Tristem M, Marshall C, Karpas A, Hill F. Evolution of the primate lentiviruses: evidence from vpx and vpr. EMBO J 1992;11:3405-3412.
24. Jones TA, Blaug G, Hansen M, Barklis E. Assembly of gag-beta-galactosidase proteins into retrovirus particles. J Virol 1990;64:2265-2279.
25. Okui N, Kobayashi N, Kitamura Y. Production of uninfectious human immunodeficiency virus type-1 containing viral protein R fused to a single-chain antibody against viral integrase. J Virol 1998;72:6960-6964.
26. Wang CT, Stegeman-Olsen J, Zhang Y, Barklis E. Assembly of HIV GAG-β-galactosidase fusion proteins into virus particles. Virology 1994;200:524-534.
27. Weldon RA Jr, Erdie CE, Oliver MG, Wills JW. Incorporation of chimeric gag protein into retroviral particles. J Virol 1990;64:4169-4179.
28. Wu X, Liu H, Xiao H, Conway JA, Hunter E, Kappes JC. Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. EMBO J 1997;16:5113-5122.
29. Wu X, Liu H, Xiao H, et al. Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx. J Virol 1995;69:3389-3398.
30. Yao X-J, Kobinger GP, Dandache S, Rougeau N, Cohen EA. HIV-1 Vpr-chloramphenicol acetyltransferase fusion proteins: sequence requirement for virion incorporation and analysis of antiviral effect. Gene Ther 1999;6:1590-1599.
31. Katz RA, Skalka AM. The retroviral enzymes. Ann Rev Biochem 1994;63:133-173.
32. Bukrinsky M, Sharova N, Stevenson M. Human immunodeficiency virus type 1 2-LTR circles reside in a nucleoprotein complex which is different from the preintegration complex. J Virol 1993;67:6863-6865.
33. BouHamdan M, Xue Y, Baudat Y, et al. Diversity of HIV-1 Vpr interactions involves usage of the WxxF motif of host cell proteins. J Biol Chem 1998;273:8009-8016.
34. Kimpton J, Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 1992;66: 2232-2239.
35. Poiesz BJ, Ehrlich GD, Byrne BC, Wells K, Kwok S, Sninsky J. In: de la Maza LM, Peterson LM, eds. Medical Virology, vol 9. New York: Plenum Press, 1990:47-75.
36. Cornetta K, Nguyen N, Morgan RA, Muenchau DD, Hartley JW, Blaese RM, Anderson WF. Infection of human cells with murine amphotropic replication-competent retroviruses. Hum Gene Ther 1993;4:579-588.
37. Salmons B, Gunzburg WH. Targeting of retroviral vectors for gene therapy. Hum Gene Ther 1993;4:129-141.
38. Goh WC, Rogel ME, Kinsey CM, et al. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med 1998;4: 65-71.
39. Wu X, Liu H, Xiao H, Kappes JC. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins. Virology 1996;219:307-313.
40. Fletcher TM, Soares MA, McPhearson S, et al. Complementation of integrase function in HIV-1 virions. EMBO J 1997;16:5123-5138.
41. Wong-Staal F, Chanda PK, Ghrayeb J. Human immunodeficiency virus: the eighth gene. AIDS Res Hum Retroviruses 1987;3:33-39.
42. Serio D, Rizvi TA, Cartas M, et al. Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication. Proc Natl Acad Sci USA 1997;94:3346-3351.
43. Liu J, Woffendin C, Yang ZY, Nabel GJ. Regulated expression of a dominant negative form of Rev improves resistance to HIV replication in T cells. Gene Ther 1994; 1:32-37.
44. Natsoulis G, Seshaiah P, Federspiel MJ, Rein A, Hughes SH, Boeke JD. Targeting of a nuclease to murine leukemia virus capsids inhibits viral multiplication. Proc Natl Acad Sci USA 1995;92:364-368.
45. Levy DN, Fernandes LS, Williams WV, Weiner DB. Induction of cell differentiation by human immunodeficiency virus 1 Vpr. Cell 1993;72:541-550.
46. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 1995;69:6705-6711.
47. Jowett JB, Planelles V, Poon B, Shah NP, Chen ML, Chen IS. The human immunodeficiency virus type 1 Vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol 1995;69:6304-6313.
48. Re F, Braaten D, Franke EK, Luban J. Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol 1995; 69:6859-6864.
49. Rogel ME, Wu LI, Emerman M. The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol 1995;69:882-888.
50. Conti L, Rainaldi G, Matarrese P, et al. The HIV-1 Vpr protein acts as a negative regulator of apoptosis in a human lymphoblastoid T cell line: possible implications for the pathogenesis of AIDS. J Exp Med 1998;187:403-413.
51. Piller SC, Jans P, Gage PW, Jans DA. Extracellular HIV-1 virus protein R causes a large inward current and cell death in cultured hippocampal neurons: implications for AIDS pathology. Proc Natl Acad Sci USA 1998;95:4595-4600.
52. Stewart SA, Poon B, Jowett JB, Chen IS. Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J Virol 1997;71:5579-5592.
53. Di Marzio P, Choe S, Ebright M, Knoblauch R, Landau NR. Mutational analysis of cell cycle arrest, nuclear localization, and virion packaging of human immunodeficiency virus type 1 Vpr. J Virol 1995;69:7909-7916.
54. Mhashilkar AM, Bagley J, Chen SY, Szilvay AM, Heiland DG, Marasco WA. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBOJ 1995;14:1542-1551.
55. Kulkosky J, BouHamdan M, Geist A, Pomerantz RJ. A novel Vpr peptide interactor fused to integrase (IN) restores integration activity to IN-defective HIV-1 virions. Virology 1999;255:77-85.
56. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362:359-362.